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cute Myocardial Infarction Study) Trials
arco Valgimigli, MD, PHD,*† Gianluca Campo, MD,* Patrizia Malagutti, MD,*
aurizio Anselmi, MD,‡ Leonardo Bolognese, MD,§ Flavio Ribichini, MD,‡
iacomo Boccuzzi, MD, Nicoletta de Cesare, MD,# Alfredo E. Rodriguez, MD, PHD,§§
ilippo Russo, MD,** Raul Moreno, MD,  Giuseppe Biondi-Zoccai, MD,¶
arlo Penzo, MD,†† José F. Dı´az Ferna´ndez, MD,¶¶ Giovanni Parrinello, PHD,‡‡
oberto Ferrari, MD, PHD*†
errara, Lumezzane, Verona, Arezzo, Turin, Zingonia, Pavia, Mirano, and Brescia, Italy;
uenos Aires, Argentina; Madrid and Huelva, Spain
bjectives These studies sought to investigate the impact on mortality of coronary ﬂow after pas-
age of the wire through the culprit vessel in patients with ST-segment elevation myocardial infarc-
ion (STEMI) undergoing mechanical reperfusion.
ackground Reduced spontaneous coronary ﬂow before percutaneous coronary intervention inﬂuences
ortality in patients with STEMI. Response to vessel wiring in patients with an occluded coronary artery be-
ore intervention might further discriminate outcomes irrespective of pre- and post-intervention coronary ﬂow.
ethods Data from the STRATEGY (Single High-Dose Bolus Tiroﬁban and Sirolimus-Eluting Stent Versus Ab-
iximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of
ingle High-Dose Bolus Tiroﬁban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute
yocardial Infarction Study) trials were pooled: of 919 index procedures, 902 ﬁlms (98%) were technically ade-
uate for core laboratory TIMI (Thrombolysis In Myocardial Infarction) ﬂow determination.
esults TIMI ﬂow grade 0 was present before percutaneous coronary intervention in 59% of infarct ves-
els, TIMI ﬂow grade 1 to 2 was found in 21%, whereas the remainder of infarct arteries presented with
IMI ﬂow grade 3. In 49% of patients who showed persistent TIMI ﬂow grade 0 after wire insertion (AWI),
ortality was higher at 30 days (5.3%) and 1 year (9.4%) compared with patients in whom TIMI ﬂow
rade before percutaneous coronary intervention was either 0 (0.8%; p  0.003 and 3.6%, p  0.008)
r improved from 0 AWI (1.5%, p  0.04 and 3.6%, p  0.02). After correcting for multiple imbalances,
ncluding baseline and ﬁnal ﬂow, persistent TIMI ﬂow grade 0 AWI remained associated at 30 days to
-fold (risk ratio [RR]: 2.1, 95% conﬁdence interval [CI]: 1.08 to 5.00; p  0.038) and at 1 year to almost
-fold increases of mortality (RR: 2.7, 95% CI: 1.3 to 5.6; p  0.008).
onclusions STEMI patients displaying persistent no-ﬂow AWI have a lower survival rate despite an ap-
arently successful mechanical intervention. As an early marker for high residual mortality risk, persistent
o-ﬂow AWI may qualify STEMI patients for dedicated pharmacomechanical treatment strategies. (J Am
oll Cardiol Intv 2011;4:51–62) © 2011 by the American College of Cardiology Foundation
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52oronary flow before intervention, graded semiquantitatively
ccording to the TIMI (Thrombolysis In Myocardial Infarc-
ion) angiographic scale, has been previously shown to influ-
nce short- (30 days) and medium-term (6 months) mortality
n patients with ST-segment elevation myocardial infarction
STEMI) undergoing percutaneous coronary intervention
PCI) (1,2). Importantly, the independent effect of initial flow
n the culprit coronary artery on survival persisted even after
orrection for post-procedural flow (1), which suggests that
See page 63
arly pre-PCI reperfusion has salutary benefits independent of
romoting ultimate restoration of TIMI flow grade 3 (2). Early
re-PCI reperfusion may improve survival by enhancing myo-
ardial recovery and/or by optimizing procedural success, of
hich final TIMI flow grade 3 is known to be a rather
nsensitive surrogate marker (3–7). A prognostic indicator for
igh residual mortality risk despite successful mechanical in-
ervention in STEMI patients would be desirable to tailor
intensity/complexity of treatment
accordingly.
We hypothesized that in pa-
tients presenting with occluded
coronary artery before inter-
vention, for whom prognosis is
known to be unfavorable (1,8),
response to vessel instrumenta-
tion through passage of the
wire may further discriminate
outcomes compared with both
pre- and post-PCI coronary
flow.
ethods
atients. Data from 2 trials—STRATEGY (Single High-
ose Bolus Tirofiban and Sirolimus-Eluting Stent Versus
bciximab and Bare-Metal Stent in Acute Myocardial
nfarction) (9) (n  175) and MULTISTRATEGY (Mul-
icenter Evaluation of Single High-Dose Bolus Tirofiban
ersus Abciximab With Sirolimus-Eluting Stent or Bare-
etal Stent in Acute Myocardial Infarction Study) (10)
n  745)—were pooled in a computerized database. The
rom the *Cardiovascular Institute, University of Ferrara, Ferrara, Italy; †Cardiovas-
ular Research Centre, Salvatore Maugeri Foundation, IRCCS, Lumezzane, Italy;
Deparof Biomedical and Surgical Sciences, Cardiology Section, University of
erona, Verona, Italy; §Cardiovascular Departments of San Donato Hospital,
rezzo, Italy; Cardiovascular Intervention Laboratory San Giovanni Bosco Hospital,
urin, Italy; ¶Division of Cardiology, University of Turin, San Giovanni Battista
ospital, Turin, Italy; #Policlinico S. Marco, Cardiology Unit, Zingonia, Italy;
*Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico S. Matteo, Cardio-
bbreviations
nd Acronyms
NOVA  analysis of
ariance
WI  after wire insertion
CI  percutaneous
oronary intervention
TEMI  ST-segment
levation myocardial
nfarction
IMI  Thrombolysis In
yocardial Infarctionascular Unit, Pavia, Italy; ††Department of Cardiology, Civic Hospital, Mirano,
taly; ‡‡Medical Statistics Unit, University of Brescia, Brescia, Italy; §§Otamendi 2ajor entry criteria of these trials were similar and deliber-
tely nonrestrictive: 74% of all-comer patients who pre-
ented to the study sites with STEMI during recruitment
eriod were included. The inclusion criteria were: 1) chest
ain for 30 min with an electrocardiographic ST-segment
levation 1 mm in 2 or more contiguous electrocardio-
ram leads, or with a new left bundle-branch block; and
) admission either within 12 h of symptom onset or
etween 12 and 24 h after onset with evidence of continuing
schemia. The exclusion criteria included administration of
brinolytics in the previous 30 days, major surgery within 15
ays, and active bleeding or previous stroke in the last 6
onths. Moreover, for both trials, to minimize the potential
or angiographic selection bias, protocols mandated inclusion
f patients immediately after clinical eligibility criteria were
et and before the visualization of coronary arteries through
ngiography (9,10). Follow-up visits were scheduled for the
TRATEGY trial at 1, 6, and 12 months and at 1, 4, 8, and
2 months for the MULTISTRATEGY trial.
tudy medications and intervention. At presentation, pa-
ients from both studies received aspirin (160 to 325 mg
rally or 250 mg intravenously, followed by 80 to 125 mg
rally indefinitely) and clopidogrel (300 mg orally and then
5 mg/day for at least 3 months). Heparin was given during
ransportation to the primary PCI facility or just in the
atheterization laboratory at 40 to 70 U/kg, targeting an
ctivated clotting time of at least 200 s. Before arterial sheath
nsertion, patients in both studies were randomly allocated with a
:1 ratio to receive tirofiban, which was given as a bolus of 25
g/kg, followed by an 18- to 24-h infusion at 0.15 g/kg/min or
bciximab, which was administered as a bolus of 0.25 mg/kg,
ollowed by a 12-h infusion at 0.125 g/kg/min. As part of a
re-specified subanalysis of both trials, the STRATEGY and
ULTISTRATEGY protocols mandated acquisition of a
oronary angiogram using the standard frame rate immedi-
tely after passage of the wire distal to the lesion to allow for
entral adjudication of TIMI flow grade after wire insertion
AWI) by an independent core laboratory. Stenting was the
efault strategy in patients with a reference vessel diameter
2.5 mm at visual estimation. Patients were randomized in
oth studies to sirolimus-eluting stent or any uncoated-stent
ype approved by the regulatory agency. The use of pre- or
ost-dilation and thrombus aspiration was left to the dis-
retion of the treating physician.
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53eﬁnitions and statistical analysis. Study end point defini-
ions have been previously reported (9–11) and were con-
istent throughout the 2 studies. All events in each study
ere reviewed by an independent adjudication committee
p to 1-year follow-up. Blood flows in the infarct vessel at
aseline, after passage of the wire, and at the end of interven-
ion were evaluated with the TIMI scale at a single indepen-
ent core angiographic laboratory for both studies (Medical
rial Analysis, Ferrara, Italy).
In particular, TIMI flow grade 0 was defined as complete
essel occlusion with no angiographic visualization of the
essel beyond site of stenosis, whereas TIMI flow grade 3
as defined as complete filling of the distal vessel by the
hird cardiac cycle.
Per protocol in both studies, investigators were asked to
lm coronary flow before (pre-PCI flow) and immediately
fter wire insertion (TIMI AWI), which was defined as
atisfactory positioning of the wire completely down the
ength of the infarct artery, and upon removal of wire after
ntervention (post-PCI flow).
Categorical variables were compared by chi-square
nalysis or Fisher exact test. Continuous variables are
resented as mean  SD and were compared by Student
test or analysis of variance (ANOVA), whereas post hoc
omparisons were performed by Tukey honest signifi-
ance difference test. To test for heterogeneity between
he 2 included studies, 3 approaches were carried out: 1)
he Q-statistic was computed for the hazard ratios for
ortality in patients with persistent occluded coronary
rtery after the wire in the 2 studies (I2  0; p  0.99);
) the Q-statistic was computed for the hazard ratios for
ortality in patients with persistent occluded coronary
rtery after the wire across different sites (n  16) that
articipated in the MULTISTRATEGY trial (I2  0;
 0.78); and 3) we compared by likelihood-ratio test 2
odels originated by including or excluding the interaction
reatment by study and confirmed that the 2 log-likelihoods
f the regression models were not improved by adding an
nteraction term (p  0.99).
After pooling of data, given the absence of heteroge-
eity, the incidence of events over time was studied by
he Kaplan–Meier method, and log-rank tests were
pplied to evaluate differences between patients based on
oronary flow graded semiquantitatively according to the
IMI angiographic scale. To assess the independent role
f baseline TIMI flow grade on mortality, the following
ariables were introduced into the Cox proportional
azards model (Cox-model 1): sex, heart rate, Killip
lass, culprit vessel, total stent length, maximal stent size,
irect stenting, time from drug bolus to first balloon
nflation, TIMI flow grade at baseline (coded as 0 vs. the
thers) and final TIMI flow grade (coded as 3 vs. the
thers), cumulative ST-segment elevation at electrocar-
iogram, and left ventricular ejection fraction at dis- gharge. Scaled Schoenfeld residuals were used to verify
he assumption of proportionality.
To further evaluate the prognostic value of TIMI flow
rade 0 after insertion of the wire, all variables included in
ables 1 and 2 as well as cumulative ST-segment elevation
efore PCI and left ventricular ejection fraction at discharge
ere tested as univariate predictors of 30-day or 1-year
ortality at Cox proportional hazards model (Cox-
odel 2). Given the limited numbers of events in relation
o the number of the studied parameters, a variable
election using the Akaike information criterion was
erformed, followed by a bootstrapped variance estima-
ion to avoid overfitting (12).
Two independent sensitivity analyses were carried out to
ssess the robustness of Cox-model 2: 1) a Cox proportional
azards model (Cox-model 3) including all variables included
n Cox-model 1 plus active smoking status, creatinine clear-
nce, total ischemic time and stent post-dilation; and 2) the
andom survival forest model, which has the advantage to
dapt to the data and is virtually model assumption free (13).
The increased discriminative value of adding TIMI AWI
as further examined with the method described by Pencina
t al. (14). This method is based on the difference between
models in the individual estimated probability that a case
ubject will be categorized as a case subject. An increased
robability that case subjects will be categorized as case subjects
nd a decreased probability that control subjects will be
ategorized as case subjects imply better prediction ability,
hereas the opposite implies worse prediction ability.
The net reclassification improvement method requires that
here exist a priori meaningful risk categories for the risk of
eath from cardiovascular causes, whereas the integrated dis-
rimination improvement considers the change in the esti-
ated prediction probabilities as a continuous variable.
All tests are 2-sided with a significance level of 0.05. All
tatistical analyses were performed using Stata (version 9.2,
tata Corp., College Station, Texas) and using the random
orest as given in the R library (15).
esults
f 919 index procedures, 902 films (98%) were technically
dequate for core laboratory TIMI flow grade determina-
ion. TIMI flow grade 0 was present before PCI in 58.9% of
nfarct vessels, suboptimal flow (TIMI flow grade 1 to 2)
as found in 21.4%, whereas the remainder of infarct
rteries presented with TIMI flow grade 3.
Compared with patients with TIMI flow grade 0 at
aseline, patients with occluded artery before PCI had
ower heart rate, were more likely to be in Killip class
reater than 1, and the right coronary artery was less
ikely to be the infarcted vessel (Table 1). They were also
ore likely to undergo multiple stenting with a final
reater stent length and receive shorter pre-treatment
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54uration with glycoprotein IIb/IIIa inhibitors before
ngiogram (Table 2).
Among patients with baseline TIMI flow grade 0, those
n whom the culprit artery remained totally occluded AWI
ere less frequently smokers, had lower creatinine clearance,
onger durations of symptoms, and underwent stent post-
ilation less often compared with patients who improved
IMI flow grade after passage of the wire (Tables 1 and 2).
mpact of baseline TIMI ﬂow grade on ﬁnal TIMI ﬂow
rade. As shown in Figure 1, final normal TIMI flow grade
Table 1. Baseline Characteristics and Oral Medicatio
B
All Patients
Age, yrs 63.4 11
Male 422 (78)
Body mass index, kg/m2 30.4 38
Diabetes 75 (14)
Hypertension 300 (55)
Smoker 206 (38.0)
Creatinine clearance, ml/min 84 32
Medical history
CABG 6 (1.1)
PCI 28 (5.2)
Myocardial infarction 46 (8.5)
Cerebrovascular accident 24 (4.4)
Presentation proﬁle
Systolic pressure, mm Hg 133 27
Heart rate, beats/min 74 19
Killip class 2 94 (17.4)
Cardiogenic shock 14 (2.6)
Symptom onset to intervention, min 210 (170–261)
3 h 196 (36.3)
3–6 h 247 (45.7)
6 h 97 (18)
Cumulative ST-segment elevation
before PCI
11.7 8.5
Medications at discharge
Aspirin 509 (94.3)
Clopidogrel 304 (56.3)
Ticlopidine 203 (37.6)
Statin 444 (82.2)
ACE-inhibitor 404 (74.8)
Beta-blocker 403 (74.6)
*Values are mean SD or n (%). p 0.1 versus baseline TIMI flow gra
TIMI flow grade 0 after wire insertion; §p 0.05 versus baseline TIMI flo
flow grade 0 after wire insertion.
ACE angiotensin-converting enzyme; CABG coronary artery byp
Myocardial Infarction.as reached in 96% to 97% of patients presenting with TIMI fow grade 0 and in 92% of patients with occluded artery at
aseline. Interestingly, in the latter group, final TIMI flow
rade 3 was successfully established in 96% of patients who
mproved TIMI flow grade after the wire and in only 89% of
hose in whom no-flow was still present after the vessel wiring.
owever, none of these differences reached statistical
ignificance.
IMI ﬂow grade, cumulative ST-segment elevation, and left
entricular ejection fraction. Cumulative ST-segment ele-
ation at transthoracic electrocardiogram immediately be-
Study Population
e TIMI Flow Grade 0
(n  540)
After Wire Insertion
TIMI Flow
Grade 0
(n  266)
TIMI Flow
Grade 1–3
(n  274)
Baseline TIMI
Flow Grade 1–3
(n  362)
63.7 11 63.2 12 64 12
205 (77) 218 (79.6) 262 (72)*
30.6 45 30 33 30 22
32 (12) 43 (15.7) 55 (15)
159 (59.8) 142 (51.8) 208 (57)
86 (32.3) 120 (43.8)† 137 (37.8)
80.8 30 86.9 35† 82 40
5 (1.9) 1 (0.4)‡ 4 (1.1)
17 (6.4) 11 (4) 16 (4.4)
27 (10.1) 19 (6.9) 29 (8.0)
10 (3.7) 14 (5.1) 18 (4.9)
133.5 27 132.8 28.6 135 26
77 20 72 20† 78 20§
54 (20.3) 40 (15.6) 41 (11.3)
8 (3) 7 (2.6) 3 (0.8)
230 (183–280) 190 (160–240)¶ 210 (170–275)
81 (30.5) 115 (42)† 134 (37)
132 (49.6) 115 (42) 162 (44.7)
53 (19.9) 44 (16.1) 66 (18.2)
12 9 11.5 8 10.6 8.2*
247 (92.8) 262 (95.6) 352 (97.2)
142 (53.4) 162 (59.1) 220 (60.8)
102 (38.3) 101 (36.9) 125 (34.5)
214 (80.4) 230 (83.9) 318 (87.8)
200 (75.2) 204 (74.4) 291 (80.3)
189 (71.1) 214 (78.1) 294 (81.2)
 0.01 versus TIMI flow grade 0 after wire insertion; ‡p 0.1 versus
e 0; p 0.01 versus baseline TIMI flow grade 0; ¶p 0.05 versus TIMI
ft; PCI percutaneous coronary intervention; TIMI Thrombolysis Inns of
aselin
de 0; †p
w grad
ass graore mechanical intervention differed based upon coronary TIMI
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55ow grade at first angiogram (p 0.002 at ANOVA). Post-hoc
nalysis revealed that it was higher in both TIMI flow
rade 0 (11.7  8.5 mm) and TIMI flow grade 1 (13 
mm) groups compared with that observed in TIMI flow
rade 3 patients (9.2  7.9 mm, p  0.002 for both)
Fig. 2A). Left ventricular ejection fraction at discharge also
aried across patients stratified according to coronary flow
efore intervention (p  0.0003 at ANOVA), with those pre-
enting with either TIMI flow grade 0 (48.2  10%) or flow
rade 1 (46.7  9%) showing lower ejection fractions than
ndividuals with TIMI flow grade 3 (51.8  10, p  0.003 for
oth at post hoc analysis) (Fig. 2A). Focusing on patients with
IMI flow grade 0 before intervention, cumulative ST-segment
levation did not differ in patients with persistent no-flow com-
ared with those who had TIMI flow grade0 AWI (12 9 vs.
1.5  7.9, respectively; p  0.46 at post hoc analysis)
Fig. 2B). However, patients presenting with TIMI flow
Table 2. Procedural Data
All Patients
Single-vessel disease 260 (48.1)
Double-vessel disease 172 (31.8)
Triple-vessel disease 105 (19.4)
Infarct-related vessel
Number evaluated 536 (99.3)
Left anterior descending coronary artery 220 (41.0)
Left circumﬂex artery 83 (15.5)
Right coronary artery 229 (42.7)
Left main coronary artery 4 (0.8)
Saphenous vein graft 0
Thrombus present† 414 (76.6)
Thrombus aspiration 72 (13.3)
Stents implanted 1.19 0.62
Length of stent, mm 25.0 13
Maximal stent size, mm 2.96 0.74
1 or more sirolimus-eluting stents implanted 237 (43.9)
1 or more bare-metal stents implanted 274 (50.7)
Direct stenting 88 (16.3)
Stent after dilation 91 (16.8)
Maximal pressure, atm 14.3 4
Abciximab therapy 275 (50.9)
Tiroﬁban therapy 265 (49.1)
Time from study drug bolus to
ﬁrst balloon inﬂation, min
46 43
*Values are n (%) or mean SD. p 0.05 versus baseline TIMI flow grade 0; †thrombus was define
grade 0;§p 0.1 versus baseline TIMI flowgrade 0; first implanted device if multiple stenting has b
0 after wire insertion.
Abbreviations as in Table 1.rade 0 who improved coronary flow after passage of the sire had significantly higher left ventricular ejection fraction
t discharge (50  9%) compared with those in whom no flow
mprovement after the wire was noted (46.4 10%, p 0.004 at
ost hoc analysis) (Fig. 2B). Interestingly, left ventricular
jection fraction in patients with baseline TIMI flow grade
yet with TIMI flow grade 0 AWI did not differ
ompared with patients with TIMI flow grade 3 before
ntervention (Fig. 2B). A similar pattern has also been noted
or the cumulative ST-segment elevation resolution strati-
ed based on pre-PCI TIMI flow grade (p  0.0001 at
NOVA) (Fig. 2C). Patients with TIMI flow grade 0 at
aseline who improved coronary flow AWI reached similar
T-segment resolution after intervention compared with
atients with spontaneous TIMI flow grade 3 before PCI
Fig. 2C).
mpact of baseline TIMI ﬂow on 30-day and 1-year out-
omes. Table 3 shows outcomes at 30 days and 1 year
eline TIMI Flow Grade 0
(0n  540)
After Wire Insertion
TIMI Flow
Grade 0
(n  266)
TIMI Flow
Grade 1–3
(n  274)
Baseline TIMI
Flow Grade 1–3
(n  362)
126 (47.4) 134 (48.9) 169 (46.7)
81 (30.4) 91 (33.2) 126 (34.8)
58 (21.8) 47 (17.2) 63 (17.4)
264 (99.3) 272 (99.3) 357 (98.6)
113 (42.8) 107 (39.1) 174 (48.7)
45 (17) 38 (14.0) 62 (17.4)
103 (39) 126 (46.3) 117 (32.8)*
2 (0.8) 2 (0.8) 3 (0.8)
— — 1 (0.3)
206 (77.4) 208 (75.9) 253 (69.6)
35 (13.2) 37 (13.5) 42 (11.6)
1.19 0.70 1.19 0.54 1.08 0.52‡
25.5 15 24.5 11 21.3 11‡
2.94 0.84 2.98 0.64 2.86 0.77§
107 (40.2) 130 (47.4) 164 (45.3)
139 (52.2) 135 (49.3) 178 (49.2)
16 (6.0) 72 (26.3)¶ 142 (39.2)‡
33 (12.4) 58 (21.2)# 66 (18.2)
14.5 4 14.1 4 14.1 4
139 (52.2) 136 (49.6) 176 (47.3)
128 (48.1) 137 (50) 187 (51.6)
48 54 43.5 26 58 115*
lling defect or haziness visible on 2 or more orthogonal views; ‡p 0.01 versus baseline TIMI flow
omplished; ¶p 0.01 versus TIMI flowgrade 0 after wire insertion; #p 0.05 versus TIMI flowgradeBas
d as a fi
een acctratified according to TIMI flow grade in the culprit vessel
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56t baseline. Mortality at 30 days was higher in patients with
IMI flow grade 0 than in remainder patients, whereas it
id not differ further in patients with nonoccluded vessel at
aseline. At 1 year, mortality was still twice as high as for
atients with nonoccluded artery at baseline, but this dif-
erence failed to reach statistical significance at univariate
nalysis. After correcting for multiple clinical and angio-
raphic imbalances, including final TIMI flow grade 3, the
resence of TIMI flow grade 0 before intervention was an
ndependent and more powerful predictor of 30-day (risk
atio [RR]: 5.2, p 0.032) and 1-year (RR: 2.1, p 0.031)
urvival than TIMI flow grade 3 after intervention (RR:
.67, p  0.13, and 1.5, p  0.39, respectively).
mpact of no-ﬂow after the wire on 30-day and 1-year
urvival. As shown in Table 3, the capability of TIMI flow
rade 0 at baseline to predict higher mortality rate at 30 days
nd 1 year was almost entirely attributable to no flow
attern AWI. Thirty-day and 1-year mortality in patients
ith no flow at baseline, who responded to vessel wiring
ith an improvement of TIMI flow grade, were similar to
atients with nontotally occluded artery before any inter-
ention (Fig. 3A). At stratified analysis, persistence of
o-flow AWI was still able to identify patients at increased
isk of 1-year mortality after exclusion of those with
uboptimal (TIMI flow grade 3) coronary flow after
ntervention (Fig. 3B). Multivariable analysis including both
IMI flow grade before and after intervention showed that
IMI flow grade 0 AWI remained associated with 2-fold
ncrease of mortality at 30 days (RR: 2.1, 95% confidence
nterval [CI]: 1.08 to 5; p  0.038) and almost 3-fold
ncrease of mortality at 1-year (RR: 2.7, 95% CI: 1.3 to 5.6;
 0.008) (Table 4). The independent value of TIMI flow
rade 0 AWI on mortality was confirmed at sensitivity
Figure 1. Impact of Initial TIMI Flow Grade on Final TIMI Flow Grade
After wire insertion (AWI) refers to the Thrombolysis In Myocardial Infarction (T
infract vessel (see text). None of these differences reached statistical signiﬁcannalyses (data not shown). pThe net reclassification improvement was estimated at
.556 (p  0.001) after the addition of TIMI AWI,
hereas the integrated discrimination improvement was
stimated at 0.038 (p  0.005).
iscussion
he main findings of our analysis can be summarized as
ollows:
. TIMI flow grade before the procedure in patients under-
going mechanical intervention was confirmed to be an
independent predictor of poor survival even when corrected
for post-procedural flow. In particular, patients with TIMI
flow grade 0 at baseline were at higher risk for short- and
long-term mortality independently from final achievement
of TIMI flow grade 3, whereas outcomes did not further
differ based on the adequacy of angiographically determined
antegrade coronary flow pre-PCI.
. Response to the passage of the wire through the culprit
lesion further discriminated outcomes in patients with
totally occluded artery at baseline. Patients with baseline
TIMI flow grade 0 in whom coronary flow AWI
improved had a fairly good prognosis, with mortality rate
in the range of 1.5% and 3.5% at 30 days and 1 year,
respectively, which did not differ from the patients with
nonoccluded artery before intervention. On the contrary, in
49% of patients with baseline occluded coronary artery in
whom passage of the wire failed to restore some antegrade
coronary flow (roughly representing 30% of the original
cohort of patients), mortality rate was remarkably higher, in
the range of 5% at 30 days and 9% at 1 year, which was not
explained by final TIMI flow grade nor by other clinical and
angiographic baseline features.
rodie et al. (2) first reported a different survival pattern in
ow grade that was established immediately after passage of the wire in theIMI) ﬂatients presenting with TIMI flow grade 2 or 3 before
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57ntervention as opposed to patients with baseline TIMI flow
rade 0/1.
Subsequently, in the pooled analysis of the PAMI (Primary
ngioplasty in Myocardial Infarction) trials, there appeared to
e a continuum of risk at univariate analysis based on initial
IMI flow grade with mortality at 6 months being 4.4% in
atients with initial TIMI flow grade 0/1, 2.8% in TIMI flow
rade 2, and 0.5% in TIMI flow grade 3 patients (1). However,
arly reperfusion with initial TIMI flow grade 3 only emerged
s independent predictor of in-hospital and medium-term
ortality after adjustment for confounders (1). This landmark
nding led to the convincing argument that early pharmaco-
ogical strategies facilitating mechanical intervention had to
ncrease the rate pre-procedural TIMI flow grade 3 to signif-
cantly improve outcomes, emphasizing the primacy of the
open-artery hypothesis.”
As a result, trials have been designed to test the early
nitiation of various antithrombotic strategies primarily
imed at increasing the rate of TIMI flow grade 3 before
ntervention (16).
Our findings expand on that and suggest that the pres-
nce of at least some anterograde coronary flow before
ntervention might be likewise beneficial in short- and
ong-term survival in patients ultimately undergoing emer-
ent mechanical intervention. The reasons for our results
eing apparently discrepant with respect to the pooled
nalysis of the PAMI trials are unclear. It should be noted
hat by protocol, patients in our study had to receive either
irofiban or abciximab before arterial sheath insertion,
hereas the use of glycoprotein IIb/IIIa inhibitors was
arginal (3%) in the PAMI trials (1). Similarly,
atients had to receive clopidogrel beyond aspirin and
nfractionated heparin at first medical contact, whereas
iclopidine was given in the emergency department only
n the PAMI Stent Pilot (17) and Randomized (18)
rials. The more potent and contemporary antiplatelet
nvironment in which mechanical intervention has been
arried out in our study versus the PAMI trials may
acilitate myocardial recovery and/or optimize myocardial
icrocirculation and thus make procedural success less
ependent on optimal spontaneous flow before interven-
ion. In keeping with our results are recent randomized or
egistry studies on facilitated PCI, where: 1) enhancing
latelet inhibition with various drugs resulted in an
mproved outcome that was paralleled by an overall
mprovement of vessel recanalization (TIMI flow grade1)
ut not necessarily by a clear increase in the rate of TIMI
ow grade 3 before intervention (6,19–21); and 2) the
resence of at least some pre-procedure TIMI flow grade0
8) or2 (21) was the only/most important predictor of left
entricular function recovery after intervention.
Our study also provides evidence that response to vessel
iring, the initial mandatory step to provide mechanical antervention, may allow us to further discriminate outcome
n patients who presented with occluded coronary artery,
ith an adjusted almost 3-fold increase in overall mortality
t 1 year in patients with persistent no-flow after positioning
f the wire along the infracted artery. Although the mech-
nisms of this finding cannot be determined with certainty
y the present study, patients with no-flow AWI had
imilar extension of the ischemic area based on cumulative
T-segment elevation, yet they tended to have a lower rate
f final TIMI flow grade 3, a suboptimal ST-segment
levation resolution after intervention, and a more depressed
eft ventricular ejection fraction at discharge than did
atients with totally occluded artery at baseline who had
mproved flow AWI. Thus, an improvement of coronary
ow AWI in patients with totally occluded infarcted artery
efore intervention may predict an improved procedural
uccess and myocardial function recovery, which provides a
echanistic explanation for the benefits seen in this patient
opulation.
Patients in whom passage of the wire is sufficient to
mprove antegrade coronary flow may have lower residual
hrombus burden, less distal microvascular obstruction, or
mproved technical success from the advantages of initial
esion delineation and road-mapping. This hypothesis is
ndirectly supported by the observation that direct stenting
as more frequently applied and that stent post-dilation,
hich may frequently trigger slow- or no-flow in the setting
f heavily thrombotic environment, was less frequently
erformed in patients with no-flow AWI. Importantly,
owever, neither direct stenting nor stent post-dilation had
ny impact on short-term or 1-year outcomes in our
ultivariable model. Although the presence of thrombus
id not differ in patients with or without wire-induced
essel recanalization, angiography is known to be an insen-
itive tool to detect and quantify coronary thrombus (22)
nd, importantly, does not provide information on throm-
us stability to mechanical disruption. Interestingly, pa-
ients with no-flow AWI were more likely to receive
ntervention beyond the 3-h window. Indeed, coronary
hrombus organizes over time (23) and becomes more
esistant to both pharmacological and mechanical fragmen-
ation. Thus, TIMI flow grade 0 AWI may constitute a
eadily available angiographic marker for partially orga-
ized, more resistant coronary thrombus, which may ham-
er optimal myocardial reperfusion under standard care.
Interestingly, Burzotta et al. (24) found manual throm-
ectomy to be particularly useful in patients with persistent
ccluded artery after the wire, which may support the
oncept that thrombus removal, more than mechanical
islodgement or pharmacological dissolution, may be espe-
ially useful in this subset of patients. Importantly, the use
f thrombus aspiration devices was equally distributed
mong the various patterns of TIMI flow grade at baseline
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58Figure 2. Impact of TIMI Flow Grade on Ejection Fraction and ST-Segment Elevation
(A) Impact of initial Thrombolysis In Myocardial Infarction (TIMI) ﬂow grade (0, 1, 2, 3) on left ventricular ejection fraction (%) assessed at discharge at transtho-
racic echocardiogram and on cumulative ST-segment elevation expressed (mm) at standard electrocardiogram obtained immediately before intervention. (B)
Impact of initial TIMI ﬂow grade with TIMI ﬂow grade 0 stratiﬁed based on coronary ﬂow AWI on left ventricular ejection fraction assessed at discharge at trans-
thoracic echocardiogram and on cumulative ST-segment elevation at standard electrocardiogram obtained immediately before intervention. PCI  percutaneous
coronary intervention; other abbreviations as in Figure 1.Continued on the next page
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59Figure 2. Continued
(C) Impact of initial TIMI ﬂow grade with TIMI ﬂow grade 0 stratiﬁed based on coronary ﬂow AWI on cumulative ST-segment elevation resolution at 90 min after
intervention at standard transthoracic electrocardiogram.Table 3. 30-Day and 1-Year Outcomes
Baseline TIMI Flow Grade 0
(n  540)
After Wire Insertion
Baseline TIMI Flow Grade
(n  362)
All Patients
TIMI Flow
Grade 0
(n  266)
TIMI Flow
Grade 1–3
(n  274) All Patients
TIMI Flow
Grade 1–2
(n  192)
TIMI Flow
Grade 3
(n  170)
30 days, n (%)
Death 18 (3.3) 14 (5.3) 4 (1.5)* 3 (0.8)* 1 (0.5) 2 (1.2)
Death or nonfatal MI 31 (5.7) 18 (6.7) 13 (4.7) 7 (1.9)* 3 (1.6) 4 (2.3)
Death, nonfatal MI, or target vessel revascularization 33 (6.1) 20 (7.5) 13 (4.7) 13 (3.6) 8 (4.2) 5 (2.9)
Deﬁnite stent thrombosis 9 (1.7) 6 (2.3) 3 (1.1) 5 (1.4) 2 (1.0) 3 (1.8)
Deﬁnite, probable stent thrombosis 14 (2.6) 10 (3.8) 4 (1.5) 5 (1.4) 2 (1.0) 3 (1.8)
1 year, n (%)
Death 35 (6.5) 25 (9.4) 10 (3.6)* 13 (3.6) 7 (3.6) 6 (3.5)
Death or nonfatal MI 52 (9.6) 33 (12.4) 19 (6.9)* 29 (8.0) 12 (6.25) 17 (10)
Death, nonfatal MI, or target vessel revascularization 83 (15.4) 48 (18.1) 35 (12.8) 51 (14.1) 23 (12.0) 28 (16.5)
Deﬁnite stent thrombosis 16 (3.0) 10 (3.8) 6 (2.2) 6 (1.7) 3 (1.6) 3 (1.8)
Deﬁnite, probable stent thrombosis 23 (4.3) 15 (5.6) 8 (2.9) 7 (1.9) 3 (1.6) 4 (2.3)
Deﬁnite, probable, possible stent thrombosis 27 (5) 17 (6.4) 10 (3.7) 12 (3.3) 7 (3.6) 5 (2.9)
*p 0.05 vs. patients with TIMI flow grade 0 after wire insertion.MImyocardial infarction; other abbreviations as inTable 1.
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60r AWI reported in our pooled analysis. Thus, it remains
ossible and worth being further explored that a more
ystematic use of thrombectomy in patients with TIMI flow
rade 0 AWI may optimize procedural success beyond the
chievement of final TIMI flow grade 3 and ultimately
itigate the impact of persistent no-flow AWI on short-
Figure 3. Cumulative Kaplan-Meier Estimates of Mortality Rates During Fo
Cumulative risk of death at 370 days in all included patients (A) or in those w
grade before mechanical treatment. Note that in both plots, patients with initi
the wire in the infracted artery into those who improved (TIMI ﬂow grade 0
and 2.nd long-term mortality risk. fAlternatively, dedicated pharmacological treatment strat-
gies able to tackle high thrombus burden (25) or target
icrocirculatory reperfusion on top of mechanical interven-
ion (26) may prove beneficial in this newly identified
igh-risk subset of STEMI patients.
Our results are in keeping with Kurowski et al. (27), who
p Period
al TIMI ﬂow grade 3 after intervention (B) stratiﬁed based on initial TIMI ﬂow
I ﬂow grade 0 have been stratiﬁed based on coronary ﬂow after insertion of
and those who did not (TIMI ﬂow grade 0 AWI). Abbreviations as in Figures 1llow-U
ith ﬁn
al TIM
AWI)ound in 311 consecutive patients with successful primary
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61CI for STEMI, reperfusion after crossing the lesion with
he guidewire to be associated to lower unadjusted mortality
ates at 30 days (3.6% vs. 9.1%) and after a median of 16
onths (3.6% vs. 13.9%, p  0.03) compared with patients
ith no flow improvement AWI. After multivariable cor-
ection, however, wire-induced recanalization only trended
o be associated to better outcomes at longest available
ollow-up (odds ratio: 0.30, 95% CI: 0.07 to 1.38; p 
.12), likely reflecting a power issue and ultimately calling
or larger datasets to reassess the association between
esponse to vessel wiring and long-term outcomes.
Mortality for STEMI has substantially decreased over the
ast 10 years thanks to a widespread use of more efficient
rimary PCI networks along with landmark pharmacome-
hanical refinements (28). The early identification of a
izable (30%) proportion of patients at 5% and 9%
ortality rate at 30 days and 1 year, respectively, may guide
uture trials to assess dedicated treatment strategies, ulti-
ately leading to a further improvement of the already
xcellent prognosis generally present after primary PCI.
tudy limitations. Although event rates in the 2 study
roups were remarkably similar, we cannot rule out the
ossibility that a power issue may explain why patients with
re-PCI TIMI flow grade 3, when compared with patients
ith TIMI flow grade 3 but 0 before intervention, did
ot have an improved survival rate . Also, although baseline
emographic differences were most likely adjusted for by the
ultivariate analyses, the effect of unknown confounders
annot be excluded. This is why confirmatory findings by
Table 4. Multivariable Cox Models for Mortality Pred
Variables p Val
Total mortality at 30 days
Heart rate (beats/min) 0.002
Left main coronary artery as culprit vessel 0.003
Killip class 1 0.034
TIMI ﬂow grade 0 after wire insertion 0.038
LVEF, % 0.05
Creatinine clearance, ml/min 0.06
Final TIMI ﬂow grade 3 vs. others 0.11
Total mortality at 12 months
Creatinine clearance, ml/min 0.000
Killip class 1 0.001
Left main coronary artery as culprit vessel 0.002
TIMI ﬂow grade 0 after wire insertion 0.005
LVEF, % 0.012
Heart rate, beats/min 0.019
Door-to-balloon time, min 0.057
The following variables were entered into themodels: creatinine clear
variable (1 vs.1); use of intra-aortic balloon pump.
CI confidence interval; LVEF left ventricular ejection fraction; other datasets are welcome.
vMyocardial blush score, which is well known to carry
rognostic implications in STEMI patients (29,30), was
ot systematically assessed in the STRATEGY and
ULTISTRATEGY trials. Thus, the independent pre-
ictive value of TIMI flow grade 0 AWI beyond the
lush score could not be evaluated. Whether and to what
xtent the prognostic role of TIMI flow grade 0 AWI is
aintained even in patients not receiving treatment with
lycoprotein IIb/IIIa inhibitors remains to be determined
s, per protocol, all patients were so in our analysis.
Finally, despite multiple multivariable models having
een employed to strengthen the results of our analysis, we
annot completely rule out the presence of overfitting due to
relatively low number of fatalities in the analysis.
onclusions
atients with STEMI in whom persistent no-flow AWI is
etected during primary PCI are at greater risk for early and
ate mortality despite an apparently successful mechanical
ntervention. As an early and readily available prognostic
arker, response to vessel wiring, may help stratifying
ortality risk after primary PCI and may guide future
tudies to identify dedicated pharmacomechanical treatment
trategies.
eprint requests and correspondence: Dr. Marco Valgimigli,
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at 30 Days and 1 Year
Hazard Ratio (95% CI) Chi-Square
52
1.03 (1.01–1.05)
50.9 (3.68–703)
3.00 (1.09–8.40)
2.10 (1.08–5.00)
0.97 (0.92–1.00)
0.98 (0.96–1.00)
1.58 (0.83–3.00)
81
0.96 (0.94–0.98)
2.80 (1.50–6.10)
50.6 (3.99–642)
2.70 (1.30–5.60)
0.95 (0.93–0.99)
1.02 (1.002–1.04)
1.002 (1.00–1.004)
x, hemoglobin at presentation, diabetes, Killip class coded as dummy
breviations as in Table 1.ictors
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